You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC

Assessing Clinical Practice in Rett Syndrome: Understanding, Knowledge, and Competence

  • Authors: Jeffrey Neul, MD, PhD
  • CME / ABIM MOC Released: 6/22/2022
  • Valid for credit through: 6/22/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for neurologists, pediatricians, and primary care providers (PCPs)

The goal of this activity is that learners will be better able to identify the educational needs of neurologists, pediatricians, and primary care providers (PCPs) with respect to Rett syndrome.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Diagnostic criteria for Rett syndrome
  • Self-assess learning needs related to
    • Clinical trial data for investigational therapies being studied for the management of Rett syndrome


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Jeffrey Neul, MD, PhD

    Professor of Pediatrics
    Division of Neurology, Pharmacology, and Special Education
    Annette Schaffer Eskind Chair and Director
    Vanderbilt Kennedy Center
    Vanderbilt University Medical Center
    Nashville, Tennessee, United States

    Disclosures

    Jeffrey Neul, MD, PhD, has no relevant financial relationships.

Editor

  • Pakinam Aboulsaoud, PharmD

    Medical Education Director, Medscape, LLC

    Disclosures

    Pakinam Aboulsaoud, PharmD, has no relevant financial relationships.

  • Megan Breuer, PhD

    Medical Writer, Medscape, LLC

    Disclosures

    Megan Breuer, PhD, has the following relevant financial relationships: Advisor/consultant Paratek Pharmaceuticals, Inc. (former)

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Assessing Clinical Practice in Rett Syndrome: Understanding, Knowledge, and Competence

Authors: Jeffrey Neul, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 6/22/2022

Valid for credit through: 6/22/2023

processing....

References

  1. Fu C, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatr Open. 2020;4:e000717.
  2. Neul JL. Can Rett syndrome be diagnosed before regression? Neurosci Biobehav Rev. 2019;104:158-159.
  3. Neul JL, et al; RettSearch Consortium. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68:944-950.
  4. Ivy AS, et al. Rett syndrome: a timely review from recognition to current clinical approaches and clinical study updates. Semin Pediatr Neurol. 2021;37:100881.
  5. Kaufmann WE, et al. ANAVEX®2-73 (blarcamesine), a sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome. Pharmacol Biochem Behav. 2019;187:172796.
  6. Kyle SM, et al. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 2018;8:170216.
  7. Cosentino L, et al. Rett syndrome before regression: a time window of overlooked opportunities for diagnosis and intervention. Neurosci Biobehav Rev. 2019;107:115-135.
  8. Glaze DG, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatr Neurol. 2017;76:37-46.
  9. Glaze DG, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92:e1912-e1925.
  10. Neul JL, et al. Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. Contemp Clin Trials. 2022;114:106704.
  11. Killian JT, et al. Scoliosis in Rett syndrome: progression, comorbidities, and predictors. Pediatr Neurol. 2017;70:20-25.
  12. Rochester MP, et al. Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence. Ther Adv Drug Saf. 2018;9:297-308.
  13. ClinicalTrials.gov. A study to evaluate ketamine for the treatment of Rett syndrome. Accessed May 24, 2022. https://clinicaltrials.gov/ct2/show/NCT03633058
  14. ClinicalTrials.gov. Pharmacological treatment of Rett syndrome with glatiramer acetate (copaxone). Accessed May 23, 2022. https://www.clinicaltrials.gov/ct2/show/NCT02153723
  15. Djukic A, et al. Pharmacologic treatment of Rett syndrome with glatiramer acetate. Pediatr Neurol. 2016;61:51-57.
  16. Nissenkorn A, et al. A potential life-threatening reaction to glatiramer acetate in Rett syndrome. Pediatr Neurol. 2017;68:40-43.
  17. Smith-Hicks CL, et al. Randomized open-label trial of dextromethorphan in Rett syndrome. Neurology. 2017;89:1684-1690.
« Return to: Assessing Clinical Practice in Rett Syndrome: Understanding, Knowledge, and Competence
  • Print